~~<i id='27DACD8D90'><strike id='27DACD8D90'><tt id='27DACD8D90'><pre id='27DACD8D90'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：focus 2025-09-27 15:19:29 - browse：4

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Custom gene therapy hints at new path for rare disease treatments

hotspot

focus

Wikipedia

entertainment

focus

knowledge

AerawasformedtopursueananoparticledescribedbyFengZhangin2021.SusanWalsh/APAeraTherapeutics,astartupl

WSS

Custom gene therapy hints at new path for rare disease treatments

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Federal weight loss drug coverage is 30 years out of date

Antibiotic resistance and the global rise in human conflict

Sanofi seeks simpler, safer CRISPR sickle cell cure

Videos point to link between seizures and unexplained toddler deaths

knowledge

knowledge

hotspot

Sports medicine is finally prioritizing gender equality

How a scoliosis diagnosis changed the life of one young dancer

Peter Hotez and the public health issue of online harassment

Feng Zhang CRISPR delivery startup lays off quarter of staff

Bright Health sells Medicare Advantage business to Molina

Sanders adds drug shortage policies to pandemic preparedness bill

Drug repurposing or repositioning? The language matters

FDA approves RSV monoclonal antibody for infants, toddlers

Duchenne breakthrough therapy leaves behind pioneering families

U.K. sequencing study surfaces new findings about tumor DNA

focus

Feng Zhang, Grail founder join forces on new gene editing startup

Feng Zhang, Grail founder join forces on new gene editing startup

How Medicaid coverage policies for immigrants impact new moms

How Medicaid coverage policies for immigrants impact new moms

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Wikipedia

entertainment

focus

knowledge